Shanghai MicroPort MedBot (Group) Co., Ltd. Class H ( (HK:2252) ) has shared an update.
Shanghai MicroPort MedBot has achieved a significant milestone with the approval of its Toumai Remote laparoscopic surgical robot by the National Medical Products Administration of China. This approval marks the world’s first for full-department application in remote surgery, enhancing the company’s product portfolio and positioning it as a leader in the global remote surgery field. The Toumai Remote system, compatible with multiple communication networks, has been instrumental in performing nearly 400 remote surgeries across various countries, showcasing its innovative capabilities and establishing numerous national and world records.
More about Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
Shanghai MicroPort MedBot (Group) Co., Ltd. operates in the medical technology industry, focusing on developing advanced surgical robotics. The company specializes in laparoscopic surgical robots, with a strong emphasis on remote surgery technology, aiming to make surgeries easier, safer, and less invasive. Their market focus includes providing intelligent solutions for hospitals and surgeons globally.
YTD Price Performance: 76.87%
Average Trading Volume: 12,965,803
Technical Sentiment Signal: Sell
Current Market Cap: HK$16.92B
See more insights into 2252 stock on TipRanks’ Stock Analysis page.